New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...

Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for ...

AstraZeneca PLC plans to invest $50 billion in the US before 2030, becoming the latest European pharma company to ratchet up ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

Lupin Limited has received approval from the United States Food and Drug Administration for its Abbreviated New Drug ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new ...

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...

Lupin receives USFDA approval for generic diabetes medications, including Liraglutide Injection and Glucagon for Injection.

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

Mumbai: Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by ...